Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.
Investigators conducted a comprehensive literature search to identify key characteristics that best differentiate between bipolar I disorder and major depressive disorder.
The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.
Investigators sought to determine the prevalence of psychotic features in patients with major depressive disorder.
Bupropion had a greater effect on reducing impulsivity and attention symptoms than escitalopram.
Patients with MDD who initially respond to antidepressant medications have a 30% to 50% chance of relapse within a year of initiating treatment.
Elevated cytokine levels could help to identify children who are unlikely to respond to treatment with fluoxetine.
Individuals suffering from depression, as well as persons diagnosed with temporal lobe epilepsy, present with dysfunction across several cognitive domains.
Cigarette smoking prevalence among persons with severe mental illness is approximately 3 times greater than the rate observed in the general population.
